Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FUROSEMIDE vs BUMEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.
Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Edema associated with heart failure, cirrhosis, renal disease,Hypertension,Hypercalcemia (off-label)
Edema associated with congestive heart failure,Edema associated with hepatic cirrhosis,Edema associated with renal disease including nephrotic syndrome
Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.
0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.
0.5-2 hours (terminal); prolonged in renal impairment (up to 9-24 hours) and hepatic cirrhosis (up to 2-4 hours).
Terminal elimination half-life: 1.5–2 hours in normal renal function; prolonged to 2.5–4 hours in severe renal impairment (Cr Cl <20 m L/min).
Furosemide is primarily metabolized via glucuronidation (by UGT1A1, UGT1A9) and to a lesser extent by CYP450 enzymes (minor).
Primarily metabolized by the liver via cytochrome P450 enzymes, including CYP2C9 and CYP3A4.
Renal (50-80% unchanged; remainder as glucuronide metabolite); fecal (<2%).
Renal: 80% as unchanged drug; biliary/fecal: 15% as metabolites; total renal elimination accounts for ~85% of clearance.
91-99% (primarily to albumin).
Bumetanide is 94–96% bound to plasma proteins (primarily albumin).
0.1-0.2 L/kg; increased in neonates (0.2-0.4 L/kg) and disease states (e.g., heart failure, cirrhosis).
0.15–0.22 L/kg; indicates primarily extracellular distribution.
Oral: 50-60% (variable, 10-100% range due to food and formulation); IM: 100% (relative to IV).
Oral bioavailability: 80–100% (mean ~95%).
GFR 10-50 m L/min: dose unchanged; GFR <10 m L/min: avoid use or use with caution; anuric patients: contraindicated.
e GFR <20 m L/min/1.73 m²: Avoid loop diuretics; consider alternative. No adjustment for mild to moderate renal impairment, but monitor response. In severe renal failure, may require higher doses due to reduced tubular secretion.
Child-Pugh A-B: no adjustment; Child-Pugh C: reduce dose by 50% and monitor response; increased risk of hypokalemia and volume depletion.
Child-Pugh Class B or C: Reduce initial dose by 50% due to impaired metabolism and increased risk of volume depletion. Titrate cautiously.
Oral: 1-2 mg/kg/dose every 6-12 hours; IV/IM: 1 mg/kg/dose every 6-12 hours; max dose: 6 mg/kg/dose. Not recommended in neonates unless critical.
Infants/Children: Oral: 0.015-0.1 mg/kg/dose once daily; maximum 10 mg/day. IV/IM: 0.015-0.1 mg/kg/dose every 12-24 hours; maximum 0.5 mg/kg/dose. Neonates: 0.01-0.05 mg/kg/dose every 24-48 hours.
Start at lowest effective dose (e.g., 20 mg orally once daily); monitor electrolytes, renal function, and volume status closely; avoid excessive diuresis.
Start at 0.5 mg orally once daily; increase cautiously due to enhanced pharmacodynamic effects and higher risk of electrolyte disturbances, volume depletion, and ototoxicity. Monitor renal function and electrolytes closely.
Furosemide is a potent diuretic; excessive diuresis may lead to profound electrolyte depletion, volume depletion, and circulatory collapse.
Bumetanide is a potent diuretic; if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule must be adjusted to individual patient's needs.
Monitor for electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia),Risk of ototoxicity, especially with rapid infusion or concurrent use of other ototoxic drugs,Monitor renal function and blood pressure; caution in patients with severe hepatic cirrhosis or renal impairment,May cause photosensitivity, blood dyscrasias, and hypersensitivity reactions
Electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Dehydration and hypovolemia,Ototoxicity (especially with rapid injection or in renal impairment),Excessive diuresis causing hypotension and thromboembolic events,May increase serum uric acid levels and precipitate gout,Risk of hypokalemia in patients with cirrhosis and ascites
Anuria,Severe electrolyte depletion,Hypersensitivity to furosemide or sulfonamides,Hepatic coma or precoma (relative)
Anuria,Hepatic coma or severe electrolyte depletion until condition is corrected,Hypersensitivity to bumetanide or sulfonamides (cross-sensitivity possible)
Avoid excessive salt intake to prevent fluid retention and counteract diuretic effect. Limit alcohol as it can increase diuretic effect and cause dehydration. May increase potassium loss; consider potassium-rich foods (bananas, oranges, spinach) unless contraindicated (e.g., with ACE inhibitors). No specific restrictions with grapefruit juice.
Avoid excessive salt intake; no specific food interactions reported. Avoid licorice as it may worsen hypokalemia. Grapefruit juice may increase bumetanide levels; use caution.
Furosemide is pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but fetal toxicity (hydronephrosis) at high doses. Second/third trimesters: Risk of electrolyte imbalance in mother and fetus, potential for decreased placental perfusion due to maternal hypovolemia. Use only if benefit outweighs risk, especially in oligohydramnios or preeclampsia.
Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are limited; no well-controlled studies exist. First trimester: theoretical risk based on animal data; avoid unless essential. Second/third trimesters: may cause maternal hypovolemia, decreased placental perfusion, and fetal oliguria; use only if clearly needed and monitor amniotic fluid volume. Neonatal risks include electrolyte imbalances and ototoxicity if used close to delivery.
Furosemide is excreted into breast milk in low amounts (M/P ratio approximately 2.6). Theoretical risk of electrolyte imbalance in infant. Consider using lowest effective dose and monitor infant for signs of dehydration or electrolyte disturbances.
Bumetanide is excreted into human milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.05-0.10. Based on limited data, amounts ingested by breastfed infants are unlikely to cause adverse effects. However, due to potential risk of hypersensitivity, electrolyte disturbances, or diuresis in the infant, caution is advised, especially in premature or renal-impaired infants. Alternative diuretics with more safety data may be preferred.
Pregnancy increases renal clearance and volume of distribution, potentially reducing plasma furosemide levels, but dosing adjustments are not routinely recommended due to risk of hypovolemia. Use lowest effective dose and titrate based on response, with close monitoring.
Pregnancy may alter bumetanide pharmacokinetics due to increased plasma volume, renal blood flow, and glomerular filtration rate. Higher doses may be required to achieve the same diuretic effect. However, no standard dose adjustment guidelines exist; use the lowest effective dose and titrate based on clinical response, monitoring for electrolyte disturbances and volume depletion. In severe preeclampsia or renal impairment, dose may need reduction. Close therapeutic drug monitoring is not routinely available; clinical monitoring of diuresis and electrolytes guides dosing.
Monitor urine output and electrolytes, especially potassium. Avoid use in anuria, severe electrolyte depletion, and hepatic coma. Can cause ototoxicity, especially with rapid IV administration or concurrent use of other ototoxic drugs. Sulfonamide allergy may cross-react; use caution. Loop diuretics like furosemide are effective in renal impairment, unlike thiazides.
Bumetanide is a loop diuretic approximately 40 times more potent than furosemide; onset of diuresis within 30-60 minutes after oral administration. Monitor for ototoxicity, especially with rapid IV administration or concurrent use of other ototoxic drugs. Hypokalemia is a common adverse effect; consider potassium supplementation or concurrent use of potassium-sparing diuretics. Contraindicated in anuria, hepatic coma, and severe electrolyte depletion. May cause hyperuricemia and precipitate gout attacks.
Take exactly as prescribed, preferably in the morning to avoid nighttime urination.,Weigh yourself daily and report rapid weight gain or loss.,Avoid alcohol and NSAIDs as they may reduce diuretic effect or increase kidney damage.,Report hearing loss, ringing in ears, dizziness, or muscle cramps immediately.,Do not stop suddenly without consulting your doctor; may cause rebound edema.,Limit high-potassium foods if also taking ACE inhibitors or potassium-sparing diuretics.,Stay hydrated but avoid excessive fluid intake.
Take this medication exactly as prescribed, typically once daily in the morning to avoid nighttime urination.,Avoid sudden position changes to prevent dizziness from low blood pressure.,Do not consume grapefruit juice or alcohol while taking this drug.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or confusion.,Weigh yourself daily and report rapid weight gain or loss to your healthcare provider.
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Zaltoprofen, a nonsteroidal anti-inflammatory drug (NSAID), reduces the antihypertensive and diuretic efficacy of furosemide by inhibiting renal prostaglandin synthesis. This blockade diminishes renal blood flow and natriuretic response, potentially leading to fluid retention and diminished blood pressure control. The interaction may precipitate or exacerbate heart failure and edema in susceptible patients."
"Isoflurane, a halogenated inhalational anesthetic, can cause dose-dependent myocardial depression and systemic vasodilation, leading to decreased blood pressure and renal perfusion. Furosemide, a loop diuretic, further reduces intravascular volume and renal blood flow via inhibition of the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle. Co-administration may result in additive hypotension, acute kidney injury, and electrolyte imbalances (e.g., hypokalemia, hypomagnesemia), particularly in patients with pre-existing renal impairment or hemodynamic instability."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FUROSEMIDE vs BUMEX, answered by our medical review team.
FUROSEMIDE is a Loop Diuretic that works by Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium ions, leading to increased urine output.. BUMEX is a Loop Diuretic that works by Bumetanide inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FUROSEMIDE and BUMEX depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FUROSEMIDE is: Adults: 20-80 mg orally once or twice daily; IV/IM: 20-40 mg once or twice daily, may increase by 20-40 mg every 6-8 hours. Max dose: 600 mg/day.. The standard adult dose of BUMEX is: 0.5-2 mg orally once daily; if inadequate response, may increase to 2-4 mg once daily or twice daily. Maximum 10 mg/day. IV: 0.5-1 mg IV over 1-2 minutes; may repeat every 2-3 hours up to 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FUROSEMIDE and BUMEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FUROSEMIDE is classified as Category A/B. Furosemide is pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but fetal toxicity (hydronephrosis) at . BUMEX is classified as Category C. Bumetanide (BUMEX) is a loop diuretic classified as FDA Pregnancy Category C. Animal studies have shown embryocidal effects and delayed ossification at high doses. Human data are l. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.